The agreement with AIFA’s and its Scientific Pricing and Reimbursement Committee (CSE) on market access for Pepaxti at a price that reflects the innovation of Pepaxti and is in line with the financial projections of the company paves the way for Oncopeptides to move forward with the regional access process. The company´s ambition is for Pepaxti to become available to patients during the first half of 2025.

The Italian market is expected to become one of Oncopeptides most important European markets with a yearly incidence of about 6,000 multiple myeloma patients, of which about 1,800 are within Pepaxti´s target population. Oncopeptides is currently conducting an Early Access Program in Italy which has included 83 patients over time emphasizing the unmet need for Pepaxti in Italy.

“With its large patient population and broad clinical experience from Pepaxti, Italy is a key market for Oncopeptides. This is great news for Italian patients suffering from relapsing, refractory multiple myeloma as as well as a major step forward for our company´s ambition to reach profitability by the end of 2026”, said Sofia Heigis, CEO of Oncopeptides.
Following the agreement with AIFA, Oncopeptides will continue strengthening its presence in Italy during the regional access phase.

“Me and the team are grateful for the support we have received by the myeloma community in Italy and in the next few weeks and months we will more than double our Italian team and invest in awareness and other premarketing activities to ensure that we build onto the already strong momentum we see in the country,” said Bruno Bolognese, Country Manager, Italy at Oncopeptides.

For more information, please visit Oncopeptides.com